Loading
Life sciences · Journal article
Lipids in Health and Disease · October 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cardiometabolic multimorbidity (CMM) is a major global public health challenge associated with metabolic dysregulation and obesity. Cholesterol, high-density lipoprotein cholesterol, and glucose (CHG) is an emerging metabolic risk index; however, the associations of CHG combined with obesity-related indices with the incidence and progression of CMM remain unclear. This study aimed to assess these associations and compare the predictive performance of eight CHG-related indices. This study included participants from the China Health and Retirement Longitudinal Study (CHARLS, 2011–2020; n = 5,355) and the English Longitudinal Study of Ageing (ELSA, 2008–2018; n = 2,096). Cumulative exposure and longitudinal exposure patterns of CHG-related indices were derived from repeated measurements. Cox regression models, multi-state Markov models, and time-dependent Receiver Operating Characteristic (ROC) curve analyses were used to assess associations and discrimination, with cross-cohort replication in ELSA. Exploratory pathway analyses were used to evaluate the potential roles of blood pressure and glucose-lipid metabolism in CMM progression. An RSF model was further developed using the CHG-related index to predict CMM risk. During a median follow-up of 5.0 and 6.0 years in the CHARLS and ELSA cohorts, respectively, 433 (8.09%) and 85 (4.06%) incident CMM cases occurred. All CHG-related indices were associated with CMM onset and progression, with cumulative exposure and exposure patterns yielding higher HRs compared to baseline measures. Among them, CuCHG-WHtR (HR = 1.68, 95% CI: 1.52–1.85) and CuCHG-WC (HR = 1.65, 95% CI: 1.49–1.81) showed stronger associations with incident CMM. CuCHG-CVAI showed a relatively prominent association with progression, with 32% and 39% higher transition risks from no cardiometabolic disease (NCMD) to first cardiometabolic disease (FCMD) and from FCMD to CMM, respectively. Findings were replicated in ELSA. Exploratory pathway analyses showed stage-specific metabolic pathways, with glycated hemoglobin and blood pressure mainly involved in early progression and dyslipidemia in advanced progression. For the RSF model incorporating CHG-WHtR, the 5-year AUC for predicting incident CMM was 0.811 (95% CI: 0.806–0.816), indicating good predictive capacity. All eight cumulative CHG-related indices were positively associated with both incident CMM and its progression, and cumulative CHG-related central obesity indices (CuCHG-WHtR and CuCHG-WC) and CuCHG-CVAI may serve as valuable indicators of incident CMM and CMM progression, respectively. Dynamic metabolic assessment may facilitate risk stratification, and stage-specific metabolic contributions may support tailored prevention strategies during CMM progression.